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The objective of this study was to develop a novel liposomal formulation, containing phosphatidylserine
(PS), of buparvaquone (BPQ) and to evaluate its in vivo effectiveness in Leishmania (L.) infantum chagasi-
infected hamsters. The activity of BPQ was evaluated against both the promastigote forms of different
Leishmania species and the intracellular amastigotes of L. (L.) infantum chagasi. Buparvaquone was
entrapped in PS-liposomes (BPQ–PS-LP), and the drug was quantiﬁed by ultra-high-performance liquid
chromatography. The treatment was quantiﬁed by detecting the RNA of the living amastigotes in the
spleen and the liver by real-time PCR. In vitro assays with L. (L.) infantum chagasi intracellular amastigotes
were performed in peritoneal macrophages for the evaluation of the 50% inhibitory concentration (IC50).
BPQ–PS-LP at 0.33 mg/kg/day for eight consecutive days reduced the number of amastigotes by 89.4%
(P < 0.05) in the spleen and by 67.2% (P > 0.05) in the liver, compared to 84.3% (P < 0.05) and 99.7%
(P < 0.05), respectively, following Glucantime treatment at 50 mg/kg/day. Free BPQ at 20 mg/kg/day
failed to treat the hamsters when compared to the untreated group. BPQ was signiﬁcantly (P < 0.05)
selective against L. (L.) infantum chagasi intracellular amastigotes, with an IC50 value of 1.5 lM; no
in vitro mammalian cytotoxicity could be detected. Other cutaneous species were also susceptible to
BPQ, with IC50 values in the range 1–4 lM. BPQ–PS-LP caused a signiﬁcant reduction in the parasite bur-
den at a 60-fold lower dose than did the free BPQ. These results show the potential of PS-liposome for-
mulations for the successful targeted delivery of BPQ in visceral leishmaniasis.
 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Leishmaniasis remains among the most important parasitic dis-
eases in the developing world. Visceral leishmaniasis (VL) has an
estimated incidence of 500,000 new cases per year and is the
life-threatening form of leishmaniasis; it is the consequence of
severe hepatosplenomegaly, which leads to death in untreated
patients (Maltezou, 2008). Epidemiologic studies indicate that
leishmaniasis is abundant in the Americas and is a great public
health concern. In the New World, the disease is caused by a num-
ber of different parasite species that are capable of producing a
wide variety of clinical manifestations: VL is usually caused by
Leishmania (L.) infantum chagasi, and cutaneous leishmaniasis
(CL) is usually caused by L. (V.) braziliensis or L. (L.) mexicana spe-
cies (Grimaldi and Tesh, 1993).
There is a shortage of safe therapeutic options to treat VL,
resulting in poor patience adherence and relapses due to the unﬁn-
ished treatments and the severe adverse effects (den Boer et al.,
2009; Murray, 2001). Outside of India, the main therapy remains
the class of pentavalent antimonials, a highly toxic option for bothl.sp.gov.br (A.G. Tempone).
sevier OA license.CL and VL. In India, where there is resistance to antimonials, the
oral drug miltefosine and the liposomal amphotericin B have
provided a signiﬁcant improvement in leishmaniasis therapy
(Maltezou, 2008; Murray, 2001). In Brazil, antimonials are still
effective for most infections despite their high toxicity, but limited
data about the resistance to these drugs is available. All current
treatments with these drugs have limitations; therefore, novel, safe
and low-cost treatments are still required (Torres et al., 2010).
Buparvaquone (BPQ) (Fig. 1), a veterinary drug used to treat
theileriosis, has shown promising activities against protozoan par-
asites, including Leishmania spp. (Croft et al., 1992), Plasmodium
falciparum (Gokhale et al., 2006), and Cryptosporidium parvum (Mül-
ler and Jacobs, 2002). Despite its anti-leishmanial activity at nano-
molar concentrations (Croft et al., 1992), in vivo experimentswith L.
(L.) donovani showed only a weak suppression of the parasite bur-
den in BALB/c mice at 100 mg/kg/day. The poor distribution and
low bioavailability of BPQ contributed to the limited in vivo efﬁcacy
in models of VL (Croft et al., 1992) and CL (Garnier et al., 2007). BPQ
was also tested at 5 mg/kg/day for 12 days in dogs infected with L.
(L.) infantum chagasi and with VL symptoms, but no effect was seen
(Vexenat et al., 1998).
The water solubility of BPQ is very low (<1 mg/L); consequently,
it is poorly soluble in biological media, such as gastric ﬂuids
Fig. 1. The chemical structure of buparvaquone.
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ity, which contributes to the low in vivo efﬁcacy of BPQ. Liposomes
have been widely used as safe and effective vehicles for drug deliv-
ery systems (Frézard and Demicheli, 2010), and liposomal ampho-
tericin B has been used to treat leishmaniasis with fewer toxic
effects (Bern et al., 2006; Sundar et al., 2011). The presence of
phosphatidylserine (PS) in the membrane of liposomes has been
shown to support the targeting delivery of drugs to intracellular
amastigotes as a result of the interaction with macrophage scaven-
ger receptors (Tempone et al., 2004, 2010). The aim of this work
was to study the efﬁcacy of BPQ entrapped in a PS-liposomal
formulation designed to deliver the drug to the infected organs,
thus providing a greater amount of the drug to the infected
macrophages.2. Materials and methods
2.1. Drugs and chemicals
3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(Thiazol blue; MTT), sodium dodecyl sulfate (SDS), M-199 medium,
RPMI-PR- 1640 medium (without phenol red) and cholesterol were
purchased from Sigma–Aldrich. Pentavalent antimony (Glucan-
time) was obtained from Aventis-Pharma-Brazil, pentamidine
was obtained from Sideron (Brazil), 2-((4-tert-Butylcyclohexyl)
methyl)-3-hydroxy-1,4-naphthoquinone (buparvaquone) was ob-
tained from GlaxoSmithKline (UK), and hydrogenated phospholip-
ids were kindly donated by Lipoid GmbH (Ludwigshafen,
Germany). The other analytical reagents were purchased from Sig-
ma (St. Louis, MO, USA).
2.2. Experimental animals
Golden hamsters (Mesocricetus auratus) and BALB/c mice were
obtained from the Instituto Adolfo Lutz of São Paulo, kept in sterile
boxes with absorbent material, and received food and water ad libi-
tum. Golden hamsters were infected each month with amastigotes
from the spleen to maintain the Leishmania strains. BALB/c mice
were used to obtain peritoneal macrophages.
2.3. Parasites and macrophages
The promastigotes of L. (L.) amazonensis (WHO/BR/00/LT0016),
L. (V.) braziliensis (MHO/BR/75/M2903), L. (L.) infantum chagasi
(MHOM/BR/1972/LD), and L. (L.) major (MHOM/1 L/80/Fredlin)
were maintained in M-199 medium supplemented with 10% calf
serum and 0.25% hemin at 24 C. L. (L.) infantum chagasi was main-
tained in Golden hamsters up to approximately 60–70 days post-
infection. The L. (L.) infantum chagasi amastigotes were obtained
from the spleens of previously infected hamsters by differential
centrifugation. The macrophages were collected from the perito-
neal cavity of BALB/c mice by washing with RPMI-1640 mediumsupplemented with 10% fetal calf serum and were maintained at
37 C and 5% CO2 in a humidiﬁed incubator.
2.4. Determination of the in vitro anti-leishmanial activity
To determine the 50% inhibitory concentration (IC50) against
Leishmania promastigotes, the drugs were dissolved in dimethyl
sulfoxide (DMSO) and diluted with M-199 medium in 96-well
microplates. The initial concentrations used were 3.06 lM
buparvaquone and 3.21 lM pentamidine. Each drug was tested
twice at eight range concentrations prepared at two-fold dilution
steps in triplicate. The promastigotes were counted in a Neubauer
hemocytometer and seeded at 1  106/well at a ﬁnal volume of
150 lL. Controls with DMSO and without drugs were performed.
Pentamidine was used as a standard drug. The plate was incubated
for 24 h at 24 C, and the viability of the promastigotes was veriﬁed
by the diphenyltetrazolium assay (MTT) (Tada et al., 1986). Brieﬂy,
MTT (5 mg/mL) was dissolved in PBS and sterilized through
0.22 lm membranes; 20 lL/well was added and incubated for 4 h
at 24 C. Promastigotes incubated without compounds were used
as the viability control. The formazan extraction was performed
using 10% SDS for 18 h (80 lL/well) at 24 C, and the optical density
(OD) was determined using a plate reader (Multiskan MS – UNI-
SCIENCE) at 550 nm. The data analysis was performed using Graph
Pad Prism 5.0 software. A viability of 100%was deﬁned based on the
optical density of the control promastigotes after normalization. To
determine the IC50 value for BPQ against L. (L.) infantum chagasi
intracellular amastigotes, peritoneal macrophages (5  104 per
well) were collected from the peritoneal cavity of BALB/c mice as
described above, added to 16-well chamber slides (NUNC), and
incubated for 24 h at 5% CO2 and 37 C. L. (L.) infantum chagasi
amastigotes were isolated from the spleens of previously infected
hamsters, separated by differential centrifugation and added to
macrophages at a ratio of 10:1 (amastigotes:macrophage). The
plate was further incubated for 24 h prior to drug incubation. Glu-
cantimewas used as the standard drug, and the test was performed
for 120 h at 37 C. The initial concentrations used were 3.06 lM
buparvaquone and 100 lg/mL Glucantime (shown in lg/mL be-
cause the molecular weight of Glucantime is unknown). Each drug
was tested twice at eight concentrations prepared as two-fold dilu-
tion steps in duplicate. At the end of the assay, the slides were ﬁxed
with methanol and stained with Giemsa prior to counting under a
light microscope. The IC50 was determined by counting 500 macro-
phages per well and assessing the number of infected macrophages
(Reimão et al., 2010).
2.5. Cytotoxicity against mammalian cells
Peritoneal macrophages, kidney cells from Rhesus monkeys
(LLC-MK-2) and tumor-human monocyte cells (THP-1) were incu-
bated with BPQ up to a concentration of 229.75 lM for 48 h at
37 C. Pentamidine was used as the reference drug. The viability
of the mammalian cells was determined using the MTT assay (Tada
et al., 1986).
2.6. BPQ entrapment in liposomes
For the liposome preparation, BPQ (6 mg) was diluted in meth-
anol (1575 lL) and sonicated in a bath sonicator for 10 minutes at
25 C (solution A). Solution B consisted of saturated egg phospha-
tidylcholine, saturated egg phosphatidylserine and cholesterol
(7:2:1 molar ratio) dissolved in chloroform (3150 lL). The mixture
of solutions A and B was further sonicated for 10 minutes. The mix-
ture was evaporated in a rotary evaporator at 55 C at 60 rpm for
40 minutes in a vacuum and protected from light. A pre-heated
(55 C) solution of 2.25% glycerol (9 mL) was added to the lipid ﬁlm
Table 1
The effect of buparvaquone (BPQ) on parasites and its cytotoxicity in mammalian cells.
L. (L.) infantum chagasi
promastigotes
L. (L.) infantum
chagasi amastigotes
L. (L.) amazonensis
promastigotes
L. (L.) major
promastigotes
L. (V.) braziliensis
promastigotes
MK2 THP-1 Peritoneal
macrophages
BPQ IC50 lM
(95% CI)
2.24 (2.05–2.45) 1.50 (1.41–1.62) 4.19 (3.61–4.87) 3.28 (2.85–
3.77)
1.50 (1.16–1.90) >229.75 >229.75 >229.75
Abbreviations: BPQ: buparvaquone; IC50: inhibitory concentration 50%; 95% CI: 95% conﬁdence interval.
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somes was performed in a rotary evaporator at 55 C at 80 rpm
for 60 minutes without a vacuum. To reduce the size of the vesi-
cles, the liposomes were sonicated in a bath sonicator under heat-
ing (55 C) for 30 minutes. A freeze-thaw process was performed
using three consecutive cycles of freezing with liquid nitrogen fol-
lowed by thawing at room temperature. The untrapped BPQ was
separated from the liposomes by centrifugation (4000g for 15 min-
utes). The average diameter of the liposomes was determined by
transmission electron microscopy using phosphotungstic acid
staining (New, 1992).
2.7. Size determination of the liposomes and the quantiﬁcation of BPQ
The concentration of the encapsulated BPQ was determined
using ultra-high-performance liquid chromatography (UPLC) with
a binary AT system (Prominence LC-20; Shimadzu Corp., Kyoto,
Japan) and an ultraviolet photodiode detector array (PDA) SPD-
M20A on a reverse phase ACE C18 column (4.6  250 mm, 5 lm
particle size). The wavelength was set at 251 nm. The ﬂow rate
was 1 mL/minute using an isocratic method with acetoni-
trile:methanol (7:3 v/v) and 0.1% triﬂuoroacetic acid (TFA). The
BPQ was diluted in methanol (1 mg/mL) to obtain standard solu-
tions in a range of 1.56–100 lg/mL, and 20 lL samples were in-
jected into the column. The standard curve showed a linear
coefﬁcient (r) of 0.9988 with the equation Y = (1.3867  105)X
+ (1.22705). The mean doses of the different liposome batches re-
sulted in a formulation of 72.63 lg/mL (SEM = 17.27) BPQ. The
mean diameter of the vesicles, as determined by transmission elec-
tron microscopy, was approximately 561 nm (SEM = 21). Consider-
ing the initial and ﬁnal masses of BPQ, the drug encapsulation
efﬁciency was approximately 11%.
2.8. Experimental studies with L. (L.) infantum chagasi-infected
hamsters
Young male Golden hamsters (110 g) were infected intraperito-
neally (i.p.) with L. (L.) infantum chagasi amastigotes (1  108/ani-
mal). Forty-three days after the infection, the hamsters were
treated for eight consecutive days as follows: BPQ at 20 mg/kg/
day, administered i.p. in two doses of 10 mg/kg at an interval of
8 h (n = 5/group); BPQ entrapped in PS-liposomes (BPQ–PS-LP) at
0.33 mg/kg/day (n = 5/group) and the pentavalent antimonial (Glu-
cantime) at 50 mg/kg/day (n = 5/group). The control group (n = 5/
group) received the BPQ vehicle (10% ethanol, 15% oil-based Crem-
ophor EL solution, and 75% PBS). The animals were euthanized
51 days post-infection. A tissue sample of the spleen and liver
(approximately 200 mg) was removed, weighed and used for
RNA extraction (Reimão et al., 2011).
2.9. Real-time PCR analysis
RNA samples were obtained from the spleen and liver frag-
ments collected from the studied hamsters, and one sample was
collected from a healthy animal and used as a negative control.
The RNA extraction from the spleen and liver samples and from
parasite cultures was carried out as previously described (Reimãoet al., 2011). All TaqMan primers and probes were selected as
previously reported (Reimão et al., 2011) and supplied by Applied
Biosystems. The ampliﬁcation runs contained two negative con-
trols (pure water and a negative DNA sample collected from a
healthy hamster) and one positive control (DNA sample extracted
from a culture of promastigotes of a standard strain of L. (L.) infan-
tum chagasi) (Reimão et al., 2011).
2.10. Statistical analysis
The data obtained were reported as the mean and standard
deviation of duplicate samples from two independent assays. The
IC50 values were calculated using sigmoid dose-response curves
generated by Graph Pad Prism 5.0 software, and the 95% conﬁ-
dence intervals were included. The Mann–Whitney test (unpaired
two-tailed) was used for signiﬁcance testing.
3. Results
3.1. In vitro anti-leishmanial activity and mammalian cytotoxicity
Different concentrations of BPQ were incubated with Leish-
mania spp. promastigotes, and the parasite viability was deter-
mined by the colorimetric MTT method. All Leishmania species
were susceptible to BPQ in the rank order (from low to high IC50
values) of L. (V.) braziliensis, L. (L.) infantum chagasi, L. (L.) major
and L. (L.) amazonensis, with IC50 values in the range of 1–4 lM
(Table 1). The IC50 of pentamidine was determined for each species
and was as follows: L. (L.) infantum chagasi (IC50 = 0.32 lM; 95%
C.I = 0.23–0.44 lM); L. (L.) amazonensis (IC50 = 0.47 lM; 95%
C.I = 0.38–0.58 lM); L. (L.) major (IC50 = 0.56 lM; 95% C.I = 0.35–
0.85 lM); and L. (V.) braziliensis (IC50 = 0.09 lM; 95% C.I = 0.03–
0.15 lM). BPQ was also active against the intracellular amastigotes
of L. (L.) infantum chagasi with an IC50 value of 1.5 lM after 120 h
incubation. No toxicity to peritoneal macrophages was observed
by light microscopy. Glucantime was used as the standard drug
and had an IC50 of 13.06 lg/mL (95% C.I = 5.15–32.73 lg/mL).
BPQ was also incubated with mammalian cells for toxicity stud-
ies. LLC-MK2 cells, THP-1 monocytes and BALB/c peritoneal macro-
phages did not show cytotoxicity at the highest concentration after
48 h (Table 1). Pentamidine was used as a reference and had an
IC50 of 11.69 lM (95% C.I = 3.02–42.95 lM) against LLC-MK2; an
IC50 of 8.22 lM (95% C.I = 4.55–14.92 lM) against THP-1 cells;
and an IC50 of 11.43 lM (95% C.I = 3.02–14.95 lM) against perito-
neal macrophages.
3.2. In vivo evaluation of free and liposomal BPQ in L. (L.) infantum
chagasi-infected hamsters
L. (L.) infantum chagasi-infected hamsters were treated i.p. for
eight consecutive days with free BPQ and BPQ entrapped in PS-lip-
osomes (BPQ–PS-LP). The parasite burden was further evaluated
and quantiﬁed by real-time PCR. The untreated group was used as
a control and resulted in an average of 1141 (standard error of
the mean, SEM = 259) amastigotes per gram in the spleen and
7234 (SEM = 4089) in the liver (Fig. 2). Free BPQ at 20 mg/kg/day
did not result in therapeutic improvement, with a mean number
Fig. 2. Real-time PCR quantiﬁcation (amastigotes per gram in spleen and liver) of
the in vivo efﬁcacy of free buparvaquone (BPQ) and liposomal BPQ (BPQ–PS-LP). The
RNA was extracted from each organ and the samples were weighed. The squares
represent free BPQ; the circles represent BPQ–PS-LP; the triangle represents
Glucantime and the lozenges represent the untreated control. ⁄P < 0.05 compared to
untreated group.
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and 8532 (SEM = 3424), respectively. BPQ–PS-LP reduced the num-
ber of amastigotes by 89.4% (P < 0.05) in the spleen and by 67.2%
(P > 0.05) in the liver, with an average of 120 (SEM = 100) amastig-
otes per gram in the spleen and 2372 (SEM = 1963) in liver. Glucan-
time at 50 mg/kg/day reduced the number of amastigotes by 84.3%
(P < 0.05) and 99.7% (P < 0.05), with an average of 179 (SEM = 71)
and 21.6 (SEM = 5.7) amastigotes/gram in the spleen and liver,
respectively. The BPQ vehicle (control group) and free liposomes
(without drugs) did not affect the parasite load (data not shown).4. Discussion
BPQ has been found to be a promising lead hydroxynaphthoqui-
none compound against Leishmania spp. Despite its high in vitro efﬁ-
cacy, with IC50 values between 0.005 and 0.12 lM (Venkatesh et al.,
2008), it showed limited efﬁcacy in L. (L.) donovani-infected mice
when tested at 100 mg/kg/day (Croft et al., 1992). Since its discovery
as an anti-leishmanial agent (Croft et al., 1992), several BPQ deriva-
tives have been proposed to overcome the elevated lipophilicity (log
P = 5.3). As an alternative, water-soluble phosphate prodrugs have
been synthesized and were tested in L. (L.) donovani-infected mice.
Buparvaquone-3-phosphate was shown to be the best oral formula-
tion, but only a slight reduction in the liver parasite burden (34%)
could be observed at 50 mg/kg/day (Garnier et al., 2007).
In the present work, BPQ exhibited in vitro activity against
Leishmania spp. when tested against the promastigote forms. The
Brazilian cutaneous species were susceptible to BPQ, which had
the lowest IC50 value in L. (V.) braziliensis. BPQ was also effective
against other species, such as L. (L.) amazonensis, L. (L.) major and
L. (L.) infantum chagasi, with a similar IC50 value to the standard
drug pentamidine. L. (L.) infantum chagasi promastigotes were also
incubated with BPQ for 72 h, but no change in the IC50 values was
detected (data not shown). BPQ could also eliminate L. (L.) infantum
chagasi intracellular amastigotes with a remarkable IC50 value
approximately 27-fold lower than the standard drug Glucantime.
Furthermore, no in vitro toxicity to mammalian cells was detected,
resulting in a selectivity index higher than 150 using the L. (L.)
infantum chagasi amastigotes. This is the ﬁrst report of the
in vitro anti-leishmanial activity of BPQ against L. (L.) infantum
chagasi and L. (V.) braziliensis. Considering the different susceptibil-
ities of the Leishmania species to BPQ, the observed IC50 value
against the intracellular amastigotes of L. (L.) infantum chagasi
was consistent with that reported for L. (L.) donovani HU3 amastig-
otes (IC50 = 0.48 lM) (Mäntylä et al., 2004).
We also report the activity of the BPQ entrapped in PS-lipo-
somes against L. (L.) infantum chagasi, the etiologic agent of VL inBrazil. In this study, BPQ–PS-LP was injected i.p. for eight consecu-
tive days, resulting in a signiﬁcant (P < 0.05) reduction of the num-
ber of amastigotes in the spleen (89.4%) when compared to the
untreated group. A slight increase in efﬁcacy (approximately 6%)
was observed for the BPQ–PS-LP when compared to the standard
drug Glucantime (P > 0.05). It should also be noted that all ham-
sters were shown to be highly infected, as conﬁrmed by real-time
PCR, therefore preventing the possibility of any false-positive
results of the drug efﬁcacy.
Despite the lack of a signiﬁcant (P > 0.05) reduction of the liver
parasite burden, the liposomal drug (BPQ–PS-LP) decreased the
number of amastigotes by 67% when compared to the untreated
group. It should also be noted that when the absolute number of
parasites is considered, 80% of animals had fewer than 1000
amastigotes per gram. The treatment differences found in the
spleen and liver of the BPQ–PS-LP-treated group could be attributed
to the huge differences in the parasite burden of both organs. To
achieve similar levels of spleen treatment, a higher amount of a
drug must be delivered in a prolonged treatment, as a consequence
of the 6-fold higher number of amastigotes in the liver when
compared to the spleen. Furthermore, the higher accumulation of
PS-liposomes in the spleen (Tempone et al., 2010) might have con-
tributed to the differences found in our assays using the BPQ–PS-LP.
Considering that BPQ–PS-LP was administered at a 60-fold
smaller dose than the free drug, these data demonstrate a consid-
erable improvement in the activity of BPQ. This could be a result of
the speciﬁc targeting delivery of BPQ to the Leishmania amastigotes
in the infected organs through the interaction of the PS-liposomes
with the macrophage scavenger receptors (Tempone et al., 2004).
In a previous work (Tempone et al., 2010), furazolidone, a synthetic
nitrofuran, when entrapped in a similar formulation of PS-lipo-
somes, showed an enhanced activity when compared to the free
drug against L. (L.) infantum chagasi experimental model. Further-
more, targeting to spleen and liver was observed, with an in vivo
co-localization of liposomes within the parasites inside the macro-
phages (Tempone et al., 2010).
Free BPQ failed to reduce the liver and spleen parasite burden in
L. (L.) infantum chagasi-infected hamsters. Despite the slight
increase in the number of amastigotes in both organs, the free
BPQ–treated group was not signiﬁcantly (P > 0.05) different than
the untreated group (control). The present data support the results
obtained from the L. (L.) infantum chagasi in naturally infected dogs
because no in vivo efﬁcacy could be detected after 12 days of treat-
ment at 5 mg/kg (Vexenat et al., 1998). In contrast, free BPQ re-
duced the parasite burden of mice liver (Croft et al., 1992)
infected with L. (L.) donovani by approximately 60% but at an oral
daily dose of 100 mg/kg. These differences in efﬁcacy could be
explained by the different doses, route of administration, the Leish-
mania species and the different animal models used.
The use of real-time PCR has been a promising tool for the rapid
evaluation of drug efﬁcacy in animal models (Manna et al., 2008;
Reimão et al., 2011) and of parasite kinetics in human blood
(Sudarshan et al., 2011). Furthermore, the speciﬁc use of RNA
allowed the detection of living amastigotes instead of dead para-
sites or residual DNA (Colombo et al., 2011), which could be found
when DNA is analyzed. Thus, the efﬁcacy of BPQ in the hamster
model could be precisely quantiﬁed in the present work.5. Conclusions
BPQ was effective in vitro against Leishmania spp., with an ele-
vated selectivity index. Free BPQ failed to treat L. (L.) infantum
chagasi-infected hamsters, but its inclusion into PS-liposomes is a
promising anti-leishmanial formulation with activity at very low
dose. Further studies, including understanding the different routes
J.Q. Reimão et al. / Experimental Parasitology 130 (2012) 195–199 199of administration and determining the 50% effective dose in single-
dose and multiple dose regimes, are now planned.Acknowledgments
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